Welcome to our dedicated page for Salarius Pharmaceuticals SEC filings (Ticker: SLRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) SEC filings page aggregates the company’s official submissions to the U.S. Securities and Exchange Commission, providing structured access to the regulatory record behind its transformation and financing activities. These documents include current reports on Form 8‑K, registration statements on Form S‑1, and proxy materials on Schedule 14A, among others.
For this issuer, Form 8‑K filings are particularly important. They detail key events such as the completion of the strategic merger with Decoy Therapeutics, the issuance of Series A and Series B Non‑Voting Convertible Preferred Stock, underwritten public offerings of common stock and warrants, reverse stock split implementation, Nasdaq listing compliance updates and notices related to minimum bid price and equity standards. One 8‑K filed in early 2026 describes a Nasdaq notice regarding non-compliance with the minimum bid price requirement and the company’s stated intention to appeal a delisting determination to a Nasdaq Hearings Panel.
Registration statements on Form S‑1 and their amendments outline the terms of public offerings, including the number of shares, pre-funded warrants, Series A and Series B warrants and representative warrants, as well as intended use of proceeds such as advancing research and development programs and addressing Decoy promissory notes. The DEF 14A definitive proxy statement provides insight into corporate governance, board elections, executive compensation proposals and the conduct of the 2025 Annual Meeting of Stockholders.
On Stock Titan, these filings are paired with AI-powered summaries that explain complex structures in accessible language, highlighting elements such as the preferred stock conversion mechanics tied to the Decoy merger, conditions for Nasdaq initial listing standards, and the implications of reverse stock splits and listing notices. Users can quickly locate quarterly and annual reports when available, review historical and current 8‑Ks, and examine equity and warrant terms without reading every page of the original documents.
Because insider transaction information for SLRX, when filed on Form 4 or related ownership forms, also appears in the SEC’s EDGAR system, this page serves as a starting point for tracking changes in beneficial ownership alongside the broader corporate actions disclosed by Salarius and its successor branding as Decoy Therapeutics.
Salarius Pharmaceuticals, Inc. (SLRX) filed a shelf registration (Form S-3) describing a range of securities it may offer, including common and preferred stock, warrants, debt and units. The prospectus explains that specific terms will be set in prospectus supplements and emphasizes reliance only on information incorporated by reference. It discloses two reverse stock splits—1-for-8 effective June 14, 2024, and a 1-for-15 effective at 5:00 p.m. ET on August 15, 2025—and states historical per-share amounts are adjusted accordingly. The document lists extensive forward-looking topics the company may discuss, including clinical development, financing needs, Nasdaq listing compliance, and liquidity. It describes governance and anti-takeover provisions in the charter and bylaws, voting and dividend rights of common stock, Series B preferred conversion mechanics (1 preferred share converts into 1,000 common shares subject to beneficial ownership limits and timing conditions), and references incorporated SEC reports and audited Decoy financials that include a going-concern explanatory paragraph.
Salarius Pharmaceuticals, Inc. effected a 1-for-15 reverse stock split of its common stock, effective August 15, 2025 at 5:00 p.m. Eastern Time. Beginning with the opening of trading on August 18, 2025, the Company’s common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under new CUSIP 79400X503. Each fifteen issued and outstanding shares were combined into one share; no fractional shares will be issued. Stockholders otherwise entitled to fractional shares will receive cash in lieu based on the closing price on the Effective Date. The reverse split does not change the number of authorized shares or par value of common or preferred stock. Outstanding options, warrants and the share reserve under the 2015 Employee Stock Purchase Plan will be adjusted in accordance with their terms. A press release announcing the reverse split was issued on August 14, 2025 and filed as Exhibit 99.1.
Salarius Pharmaceuticals, Inc. reported a six-month net loss of $2.67 million and a quarter-end cash balance of $794,886 as of June 30, 2025, with an accumulated deficit of $84.6 million. Operating expenses declined year-over-year driven by cost-savings actions and curtailed sponsored trials, reducing six-month R&D to $191,915 and G&A to $2.49 million. Working capital was negative and stockholders' equity was a deficit of $829,724 at June 30, 2025.
The filing discloses material liquidity and listing risks: Nasdaq notified the company of noncompliance with minimum bid-price and equity standards and a Hearings Panel granted time-limited extensions contingent on milestones. Salarius entered a merger agreement with Decoy and amended terms that materially reduce legacy Salarius ownership to 7.6% post-merger under Amendment No.2. Subsequent to quarter-end, Salarius sold shares under its ELOC for gross proceeds of approximately $3.8 million, and stockholders approved removal of the ELOC exchange cap and a possible reverse split.
On 18 Jul 2025 Salarius Pharmaceuticals (SLRX) executed a Third Amendment to its pending merger agreement with Decoy Therapeutics. The change enables certain Decoy note-holders to swap outstanding non-convertible promissory notes for newly created Series B Non-Voting Convertible Preferred Stock. The exchange ratio for Salarius (7.6%) and Decoy (92.4%) shareholders remains unchanged on a fully-diluted, pre-financing basis, thereby preserving previously disclosed ownership economics.
Key Series B terms: 1,000 common shares per preferred share (same as Series A) but (i) voluntary conversion any time after stockholder & Nasdaq listing approval, (ii) automatic conversion one year after such approval, (iii) mandatory redemption funded with 50% of net cash raised through Salarius’s existing ATM or equity line until all Series B shares are retired, and (iv) optional company-initiated redemption with seven days’ notice. Redemption price equals the lower of the S-1 offering price×1,000 or 1,000×weighted-average price of any subsequent ≥$2 m equity raise.
The amendment effectively converts Decoy debt into equity, reducing leverage and clearing a closing condition. However, earmarking half of future capital-raise proceeds for redemptions could constrain post-merger liquidity. All other merger terms remain intact; the note exchange will settle immediately after the merger closes.
Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) convened a Special Meeting of Stockholders on July 8, 2025. Of the 2,127,286 common shares outstanding on the May 13, 2025 record date, 789,213 shares (37.10%) were present in person or by proxy, satisfying quorum requirements.
Key matters approved
- Reverse Stock Split: Stockholders authorized the Board to implement a reverse split in a ratio between 1-for-4 and 1-for-40 at the Board’s discretion (Votes For: 561,364; Against: 224,901; Abstain: 2,678).
- Nasdaq 20% Issuance: Approved issuance of additional common shares under the December 12, 2024 Securities Purchase Agreement with C/M Capital Master Fund, LP without the exchange-cap limitation, satisfying Nasdaq Listing Rules 5635(a) & 5635(d) (Votes For: 124,631; Against: 73,764; Abstain: 1,095; Broker Non-Votes: 589,723).
- Adjournment Proposal: Granted authority to adjourn the meeting to solicit more proxies if needed (Votes For: 598,521; Against: 187,750; Abstain: 2,942). An adjournment ultimately was not required.
No other matters were brought before the meeting, and the filing contains no financial performance data. The Board now possesses flexibility to manage share structure (reverse split) and finalize the previously agreed financing transaction, both of which can influence future capitalization and compliance with Nasdaq listing standards.